Psychopharmacology
October 2018
Ruin Moaddel, Michelle Shardell, Mohammed Khadeer et al.
(R,S)-Ketamine produces rapid, robust, and sustained antidepressant effects in major depressive disorder. Specifically, its pharmacological efficacy in treatment refractory depression is considered a major breakthrough in the field. However, the mechanism of action of ketamine's rapid effect remains to be determined. In order to identify pathways that are responsible for ketamine's effect, a...
Medical Hypotheses
October 2018
Jakub Słupski, Wiesław Jerzy Cubała, Natalia Górska et al.
Depression is one of the most common psychiatric issues with a proportion of adults with major depressive disorder who fail to achieve remission with index pharmacological treatment. There are unmet needs in ADT focus on non-monoaminergic agents. Accumulating evidence suggests that the N-Methyl-d-aspartate receptor (NMDAR) plays an important role in the neurobiology and treatment of major...
Journal of Psychopharmacology
October 2018
Rejish K Thomas, Glen B. Baker, John Lind et al.
Intravenous ketamine has been established as an efficacious and safe treatment, with transient effect, for treatment-resistant depression. However, the effectiveness of intravenous ketamine in non-research settings and with ultraresistant depression patients remains understudied. This study aims to measure the response and remission rates in ultraresistant depression patients in a clinical...
Journal of Psychosocial Nursing and Mental Health Services
October 1, 2018
Barbara J. Limandri
Treatment-resistant depression (TRD) is a disabling and demoralizing phenomenon for patients and clinicians. For many years, treatment for depression has relied on the monoamine theory, with medications limited in efficacy and requiring prolonged use before any therapeutic effects are evident. The current article reviews novel approaches to pharmacological treatment of TRD, including...
Journal of Psychopharmacology
September 27, 2018
Yanling Zhou, Wei Zheng, Weijian Liu et al.
74 citations
BACKGROUND: Ketamine has proven to have rapid, robust antidepressant effects on treatment-resistant depression. However, whether repeated ketamine infusions would cause short-and long-term neurocognitive impairments was not clear. Our aims were to investigate the neurocognitive effects of six ketamine infusions and to examine the association between these infusions and the antidepressant...
The British Journal of Psychiatry
September 24, 2018
Yoav Domany, Maya Bleich‐Cohen, Ricardo Tarrasch et al.
117 citations
BACKGROUND: Ketamine has been demonstrated to improve depressive symptoms.AimsEvaluation of efficacy, safety and feasibility of repeated oral ketamine for out-patients with treatment-resistant depression (TRD). METHOD: In a randomised, double-blind, placebo-controlled, proof-of-concept trial, 41 participants received either 1 mg/kg oral ketamine or placebo thrice weekly for 21 days...
Neurobiology of Stress
September 21, 2018
Caroline E. Strong, Mohamed Kabbaj
60 citations
In this review, we will discuss the safety of repeated treatments with ketamine for patients with treatment-resistant depression (TRD), a condition in which patients with major depression do not show any clinical improvements following treatments with at least two antidepressant drugs. We will discuss the effects of these treatments in both sexes at different developmental periods. Numerous...
Biological Psychiatry
September 20, 2018
Samuel T. Wilkinson, Paul E. Holtzheimer, Shan Gao et al.
Until recently, therapeutic development in psychiatry was targeted solely toward symptom reduction. While this is a worthwhile goal, it has yielded little progress in improved therapeutics in the last several decades in the field of mood disorders. Recent advancements in our understanding of pathophysiology suggests that an impairment of neuroplasticity may be a critical part of the development...
Iranian Journal of Psychiatry and Behavioral Sciences
September 15, 2018
Abdollah Omidi, Sajedeh Hamidian
6 citations
Background: Comorbidity of anxiety and mood disorders is rather common, making the treatment of each disorder more difficult. Posttraumatic stress disorder (PTSD) is one of the anxiety disorders with a high degree of association with depression; PTSD-depression comorbidity can significantly affect the quality of life of the ones affected. Hence, using the best way to deal with each of these...
World Psychiatry
September 7, 2018
Michaela Irwin, D. Piber
tial impact of psychedelic drugs on psychiatry to that of the microscope on biology and, while this analogy may strike some as laughable, let us reflect for a moment that human research with psychedelics has been effectively moribund since the restrictive drug policy reforms of the 1960s-70s, and has only recently been revived. Classic serotonergic psychedelics – such as LSD, psilocybin and...